B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF
    1.
    发明申请
    B7-H4 FUSION PROTEINS AND METHODS OF USE THEREOF 有权
    B7-H4融合蛋白及其使用方法

    公开(公告)号:US20120276095A1

    公开(公告)日:2012-11-01

    申请号:US13392811

    申请日:2010-08-31

    摘要: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

    摘要翻译: 公开了含有B7-H4多肽的融合蛋白。 B7-H4融合蛋白可以包括全长B7-H4多肽,或者可以含有全长B7-H4多肽的片段,包括B7-H4多肽的一些或全部细胞外结构域。 还公开了使用融合蛋白来下调T细胞活化和治疗炎性和自身免疫性疾病和病症的方法。 B7-H4融合蛋白可用于通过抑制或减少Th1,Th17,Th22和/或分泌或引起其他细胞的其他细胞的分化,增殖,活性和/或细胞因子产生和/或分泌来治疗炎症 包括但不限于IL-1和bgr; TNF-α,TGF-β,IFN-γ,IL-17,IL-6,IL-23,IL-22,IL-21, 和MMPs; 或增强Treg的IL-10分泌,增加Treg的分化,增加Treg的数量或其组合。

    B7-H4 fusion proteins and methods of use thereof
    2.
    发明授权
    B7-H4 fusion proteins and methods of use thereof 有权
    B7-H4融合蛋白及其使用方法

    公开(公告)号:US09011853B2

    公开(公告)日:2015-04-21

    申请号:US13392811

    申请日:2010-08-31

    摘要: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1β, TNF-α, TGF-beta, IFN-γ, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.

    摘要翻译: 公开了含有B7-H4多肽的融合蛋白。 B7-H4融合蛋白可以包括全长B7-H4多肽,或可以含有全长B7-H4多肽的片段,包括B7-H4多肽的一些或全部细胞外结构域。 还公开了使用融合蛋白来下调T细胞活化和治疗炎性和自身免疫性疾病和病症的方法。 B7-H4融合蛋白可用于通过抑制或减少Th1,Th17,Th22和/或分泌或引起其他细胞的其他细胞的分化,增殖,活性和/或细胞因子产生和/或分泌来治疗炎症 包括但不限于IL-1和bgr; TNF-α,TGF-β,IFN-γ,IL-17,IL-6,IL-23,IL-22,IL-21, 和MMPs; 或增强Treg的IL-10分泌,增加Treg的分化,增加Treg的数量或其组合。